ABRAXANE Powder for suspension for infusion Ref.[7797] Active ingredients: Paclitaxel

Source: European Medicines Agency (EU)  Revision Year: 2019  Publisher: Celgene Europe B.V., Winthontlaan 6 N, 3526 KV Utrecht, Netherlands

Product name and form

Abraxane 5 mg/ml powder for suspension for infusion.

Pharmaceutical Form

Powder for suspension for infusion.

The reconstituted suspension has a pH of 6-7.5 and an osmolality of 300-360 mOsm/kg.

The powder is white to yellow.

Qualitative and quantitative composition

Each vial contains 100 mg of paclitaxel formulated as albumin bound nanoparticles.

Each vial contains 250 mg of paclitaxel formulated as albumin bound nanoparticles.

After reconstitution, each ml of suspension contains 5 mg of paclitaxel formulated as albumin bound nanoparticles.

Excipients with known effect: Each ml of concentrate contains 0.183 mmol sodium, which is 4.2 mg of sodium.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Paclitaxel

Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability results in the inhibition of the normal dynamic reorganisation of the microtubule network that is essential for vital interphase and mitotic cellular functions.

List of Excipients

Human albumin solution (containing sodium, sodium caprylate and N-acetyl DL tryptophanate)

Pack sizes and marketing

50 ml vial (type 1 glass) with a stopper (butyl rubber), with an overseal (aluminium), containing 100 mg of paclitaxel formulated as albumin bound nanoparticles.

100 ml vial (type 1 glass) with a stopper (butyl rubber), with an overseal (aluminium), containing 250 mg of paclitaxel formulated as albumin bound nanoparticles.

Pack size of one vial.

Marketing authorization holder

Celgene Europe B.V., Winthontlaan 6 N, 3526 KV Utrecht, Netherlands

Marketing authorization dates and numbers

EU/1/07/428/001

EU/1/07/428/002

Date of first authorisation: 11 January 2008

Date of latest renewal: 14 January 2013

Drugs

Drug Countries
ABRAXANE Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.